VBLT News and Press, Vascular Biogenics Ltd. From 11/06/19

Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a...

TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

Vascular Biogenics Ltd. (VBLT) Q2 2019 Earnings Conference Call August 13, 2019 8:30 AM ET Company Participants Michael Wood – LifeSci Advisors Dror Harats – Chief Executive Officer Amos Ron – Chief Financial Officer Conference Call Participants Kevin D...

VBL Therapeutics (NASDAQ: VBLT ): Q2 GAAP EPS of -$0.13 in-line. More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update. “Our OVAL Phase 3 potential-registration trial of VB-111 in ovarian cancer continues as...

TEL AVIV, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

TEL AVIV, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that its new gene therapy manufacturing facility i...

Thinly traded nano cap Vascular Biogenics ( VBLT +8.7% ) perks up on almost 20% higher volume, albeit on turnover of only 108K shares, on the heels of new coverage at Oppenheimer who rates it Outperform with a $2 (57% upside) price target. More news on: Vascular Biogenics Ltd., Healthcar...

The following slide deck was published by Vascular Biogenics Ltd. in conjunction with this Read more ...

TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:  VBLT ), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the rec...